Death and distant rumours
This article was originally published in Scrip
The German publications Der Spiegel and Die Zeit reported as news on 11 November 2011 that some 260 deaths from bleeding had occurred in patients taking Boehringer Ingelheim’s stroke prevention pill Pradaxa. That figure seemed - to those publications and to others - to be at odds with Boehringer's statement in early November that 50 reported deaths was a "reasonable order of magnitude".
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.